{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:17:38Z","timestamp":1758046658392,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.pharma.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:39:02Z","timestamp":1629455942000},"page":"312-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Consommation des stup\u00e9fiants, substances assimil\u00e9es aux stup\u00e9fiants et psychotropes en \u00e9tablissement de sant\u00e9\u00a0: profil d\u2019un h\u00f4pital fran\u00e7ais et d\u2019un h\u00f4pital qu\u00e9b\u00e9cois"],"prefix":"10.1016","volume":"80","author":[{"given":"M.","family":"Videau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aussedat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-1700","authenticated-orcid":false,"given":"D.","family":"Lebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-4967","authenticated-orcid":false,"given":"J.-F.","family":"Bussi\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Prise en charge de l\u2019abus de substances psychoactives. Informations sur l\u2019overdose d\u2019opio\u00efdes. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0330"},{"year":"1996","series-title":"Cancer pain relief. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0335"},{"key":"10.1016\/j.pharma.2021.08.003_bib0340","unstructured":"International Narcotics Control Board. Availability of narcotic drugs for medical use. [En ligne] Disponible\u00a0: https:\/\/www.incb.org\/incb\/fr\/narcotic-drugs\/Availability\/availability.html [Consult\u00e9 le 15\u00a0novembre 2020]."},{"year":"2015","series-title":"United Nations population data. Opioid Consumption Maps\u2013Morphine, mg\/capita<\/BT>, 2015. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0345"},{"key":"10.1016\/j.pharma.2021.08.003_bib0350","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.pharma.2021.08.003_bib0355","unstructured":"Centers for Disease Control and Prevention (CDC). Wide-ranging online data for epidemiologic research (WONDER). [En ligne]. https:\/\/wonder.cdc.gov\/.[Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0360","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention. Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants \u2014 United States, 2015\u20132016; 2018. [En ligne] Disponible : https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6712a1.htm [Consult\u00e9 le 15 novembre 2020].","DOI":"10.15585\/mmwr.mm6712a1"},{"key":"10.1016\/j.pharma.2021.08.003_bib0365","unstructured":"Gouvernement du Canada. Apparent opioid-related deaths. [En ligne] Disponible\u00a0: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-abuse\/prescription-drug-abuse\/opioids\/apparent-opioid-related-deaths.html [Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0370","unstructured":"Nations Unies. Convention unique sur les stup\u00e9fiants de 1961; 1961. [En ligne] Disponible : https:\/\/www.incb.org\/documents\/Narcotic-Drugs\/1961-Convention\/convention_1961_fr.pdf [Consult\u00e9 le 15 novembre 2020]."},{"year":"2017","series-title":"Les Conventions internationales relatives au contr\u00f4le des drogues. Tableaux de la Convention sur les substances psychotropes de 1971. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0375"},{"key":"10.1016\/j.pharma.2021.08.003_bib0380","unstructured":"Nations Unies. Les Conventions Internationales Relatives Au Contr\u00f4le Des Drogues. \u0422\u0430bleaux de la Convention des Nations Unies contre le trafic illicite de stup\u00e9fiants et de substances psychotropes de 1988 [En ligne]. 2017."},{"key":"10.1016\/j.pharma.2021.08.003_bib0385","unstructured":"International Narcotics Control Board (INCB). Narcotic drugs technical report: Estimated world requirements for 2015 - statistics for 2013; 2017. [En ligne] Disponible : https:\/\/www.incb.org\/incb\/en\/narcotic-drugs\/Technical_Reports\/2016\/narcotic-drugs-technical-report-2016.html [Consult\u00e9 le 15 novembre 2020]."},{"issue":"1","key":"10.1016\/j.pharma.2021.08.003_bib0390","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejp.1291","article-title":"Prescription opioid analgesic use in France: trends and impact on morbidity-mortality","volume":"23","author":"Chenaf","year":"2019","journal-title":"Eur J Pain"},{"issue":"6","key":"10.1016\/j.pharma.2021.08.003_bib0395","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bcp.13564","article-title":"Trends in analgesic consumption in France over the last 10\u00a0years and comparison of patterns across Europe","volume":"84","author":"Hider-Mlynarz","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2021.08.003_bib0400","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Policy and practice birefings\u2013Reducing opioid-related deaths. [En ligne] Disponible\u00a0: http:\/\/www.emcdda.europa.eu\/best-practice\/briefings\/reducing-opioid-related-deaths_en [Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0405","unstructured":"La lettre du pharmacologue. Dossier Antalgiques par Pr Nicolas Authier; 2017. [En ligne] Disponible : http:\/\/www.ofma.fr\/wp-content\/uploads\/2017\/11\/article-Barreau-et-al-2017-Lettre-Pharmacologue.pdf [Consult\u00e9 le 15 novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0410","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2105\/AJPH.2014.302147","article-title":"Moving beyond misuse and diversion: the urgent need to consider the role of iatrogenic addiction in the current opioid epidemic","volume":"104","author":"Beauchamp","year":"2014","journal-title":"Am J Public Health"},{"key":"10.1016\/j.pharma.2021.08.003_bib0415","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.drugalcdep.2016.04.002","article-title":"Physician continuing education to reduce opioid misuse, abuse, and overdose: many opportunities, few requirements","volume":"163","author":"Davis","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharma.2021.08.003_bib0420","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jama.2011.370","article-title":"Association between opioid prescribing patterns and opioid overdose-related deaths","volume":"305","author":"Bohnert","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2021.08.003_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J069v27n01_01","article-title":"The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits","volume":"27","author":"Wisniewski","year":"2008","journal-title":"J Addict Dis"},{"year":"2005","series-title":"Under the counter. the diversion and abuse of controlled prescription drugs in the U.S [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0430"},{"key":"10.1016\/j.pharma.2021.08.003_bib0435","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jpain.2010.02.019","article-title":"Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base","volume":"11","author":"Chapman","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.pharma.2021.08.003_bib0440","unstructured":"Centers for Disease Control and Prevention (CDC). U.S. Opioid Prescribing Rate Maps; 2020. [En ligne]. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html [Consult\u00e9 le 15 novembre 2020]."},{"issue":"7","key":"10.1016\/j.pharma.2021.08.003_bib0445","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1302\/0301-620X.99B7.BJJ-2016-1350.R1","article-title":"An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next?","volume":"99\u2013B","author":"Helmerhorst","year":"2017","journal-title":"Bone Joint J"},{"key":"10.1016\/j.pharma.2021.08.003_bib0450","doi-asserted-by":"crossref","first-page":"g1251","DOI":"10.1136\/bmj.g1251","article-title":"Rate and risk factors for prolonged opioid use after major surgery: population based cohort study","volume":"348","author":"Clarke","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pharma.2021.08.003_bib0455","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101014","article-title":"Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review","volume":"4","author":"Gentile","year":"2020","journal-title":"BJGP Open"},{"key":"10.1016\/j.pharma.2021.08.003_bib0460","unstructured":"Arr\u00eat\u00e9 du 22\u00a0f\u00e9vrier 1990\u00a0fixant la liste des substances class\u00e9es comme stup\u00e9fiants (version consolid\u00e9e du 8\u00a0novembre 2015). [En ligne] Disponible\u00a0: https:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/806cd6fa818861e96e274bf6645a5162.pdf [Consult\u00e9 le 15\u00a0novembre 2020]."},{"year":"2015","series-title":"M\u00e9dicaments Assimil\u00e9s Stup\u00e9fiants. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0465"},{"year":"2013","series-title":"Dur\u00e9e maximale de prescription des m\u00e9dicaments class\u00e9s comme hypnotiques. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0470"},{"year":"2013","series-title":"Dur\u00e9e maximale de prescription des m\u00e9dicaments class\u00e9s comme anxiolytiques [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0475"},{"key":"10.1016\/j.pharma.2021.08.003_bib0480","unstructured":"Loi r\u00e9glementant certaines drogues et autres substances (L.C. 1996, ch. 19). [En ligne] Disponible\u00a0: http:\/\/laws-lois.justice.gc.ca\/fra\/lois\/C-38.8\/page-1.html#h-2 [Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0485","unstructured":"Government of Canada. Controlled Substances and Precursor Chemicals; 2020. [En ligne] Disponible : https:\/\/www.canada.ca\/fr\/sante-canada\/services\/preoccupations-liees-sante\/substances-controlees-precurseurs-chimiques.html [Consult\u00e9 le 15 novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0490","unstructured":"R\u00e8glement sur les stup\u00e9fiants. C.R.C., ch. 1041. A jour au 20\u00a0juin 2018. [En ligne] Disponible\u00a0: http:\/\/laws-lois.justice.gc.ca\/PDF\/C.R.C.,_c._1041.pdf [Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0495","unstructured":"R\u00e8glement sur les aliments et drogues (C.R.C., ch. 870). A jour 20\u00a0juin 2018. [En ligne] Disponible\u00a0: http:\/\/laws-lois.justice.gc.ca\/fra\/reglements\/C.R.C.,_ch._870\/ [Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0500","unstructured":"R\u00e8glement sur les benzodiaz\u00e9pines et autres substances cibl\u00e9es (DORS\/2000-217). \u00c0 jour 20\u00a0juin 2018. [En ligne] Disponible\u00a0: http:\/\/laws.justice.gc.ca\/fra\/reglements\/DORS-2000-217\/index.html [Consult\u00e9 le 15\u00a0novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0505","unstructured":"Gouvernement du Canada. La Gazette du Canada, Partie I, volume 153, num\u00e9ro 16 : R\u00e8glement modifiant le R\u00e8glement sur les stup\u00e9fiants (tramadol); 2019. [En ligne] Disponible : https:\/\/gazette.gc.ca\/rp-pr\/p1\/2019\/2019-04-20\/html\/reg2-fra.html [Consult\u00e9 le 18 mars 2021]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0510","unstructured":"World Health Organization Collaborating centre for drug statistics methodology. ATC\/DDD Index 2018; 2020. [En ligne] Disponible : https:\/\/www.whocc.no\/atc_ddd_index\/ [Consult\u00e9 le 15 novembre 2020]."},{"issue":"5","key":"10.1016\/j.pharma.2021.08.003_bib0515","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/pds.4168","article-title":"Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment","volume":"26","author":"Nielsen","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.pharma.2021.08.003_bib0520","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269216311398300","article-title":"Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses","volume":"25","author":"Svendsen","year":"2011","journal-title":"Palliat Med"},{"issue":"6","key":"10.1016\/j.pharma.2021.08.003_bib0525","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3945","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.pharma.2021.08.003_bib0530","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jpainsymman.2004.07.010","article-title":"Use of opioids in a Danish population-based cohort of cancer patients","volume":"29","author":"Jarlbaek","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.pharma.2021.08.003_bib0535","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1472-6963-14-90","article-title":"Trends and changes in prescription opioid analgesic dispensing in Canada 2005\u20132012: an update with a focus on recent interventions","volume":"14","author":"Fischer","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"26","key":"10.1016\/j.pharma.2021.08.003_bib0540","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006\u20132015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10028","key":"10.1016\/j.pharma.2021.08.003_bib0545","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(16)00161-6","article-title":"Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study","volume":"387","author":"Berterame","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2021.08.003_bib0550","unstructured":"Arr\u00eat\u00e9 du 31\u00a0mars 1999\u00a0modifi\u00e9 fixant les sp\u00e9cifications techniques des ordonnances mentionn\u00e9es \u00e0 l\u2019article R. 5194\u00a0du CSP."},{"key":"10.1016\/j.pharma.2021.08.003_bib0555","unstructured":"Arr\u00eat\u00e9 du 22\u00a0f\u00e9vrier 1990\u00a0relatif aux conditions de d\u00e9tention des substances et pr\u00e9parations class\u00e9es comme stup\u00e9fiants (JORF du 7\u00a0juin 1990)."},{"key":"10.1016\/j.pharma.2021.08.003_bib0560","unstructured":"Arr\u00eat\u00e9 du 1er avril 2008\u00a0relatif \u00e0 la liste de soins ou traitements susceptibles de faire l\u2019objet de m\u00e9susage, d\u2019un usage d\u00e9tourn\u00e9 ou abusif, pris en application de l\u2019article L. 162-4-2\u00a0du CSS."},{"key":"10.1016\/j.pharma.2021.08.003_bib0565","unstructured":"Arr\u00eat\u00e9 du 12\u00a0mars 2013\u00a0relatif aux substances, pr\u00e9parations, m\u00e9dicaments class\u00e9s comme stup\u00e9fiants ou soumis \u00e0 la r\u00e9glementation des stup\u00e9fiants dans les \u00e9tablissements de sant\u00e9, les groupements de coop\u00e9ration sanitaire, les groupements de coop\u00e9ration sociale et m\u00e9dico-sociale, les \u00e9tablissements m\u00e9dico-sociaux mentionn\u00e9s \u00e0 l\u2019article R. 5126-1\u00a0du code de la sant\u00e9 publique et les installations de chirurgie esth\u00e9tique satisfaisant aux conditions pr\u00e9vues \u00e0 l\u2019article L. 6322-1\u00a0de ce m\u00eame code et disposant d\u2019une pharmacie \u00e0 usage int\u00e9rieur - L\u00e9gifrance [Internet]. Disponible sur\u00a0: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000027199914\/ [cit\u00e9 21\u00a0nov 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0570","unstructured":"Arr\u00eat\u00e9 du 12\u00a0juillet 2017\u00a0portant modification des exon\u00e9rations \u00e0 la r\u00e9glementation des substances v\u00e9n\u00e9neuses. JORF no\u00a00165\u00a0du 16\u00a0juillet 2017. texte no\u00a05."},{"issue":"50\u201351","key":"10.1016\/j.pharma.2021.08.003_bib0575","first-page":"1378","article-title":"Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014","volume":"64","author":"Udd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.pharma.2021.08.003_bib0580","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9. Outils de surveillance et d\u2019\u00e9valuation - R\u00e9sultats d\u2019enqu\u00eates. [En ligne] Disponible\u00a0: https:\/\/ansm.sante.fr\/Declarer-un-effet-indesirable\/Pharmacodependance-Addictovigilance\/Outils-de-surveillance-et-d-evaluation-Resultats-d-enquetes\/(offset)\/5#paragraph_92017 [Consult\u00e9 le 15\u00a0novembre 2020]."},{"year":"2019","series-title":"\u00c9valuation des pratiques professionnelles anesth\u00e9siques au bloc op\u00e9ratoire d\u2019Antibes suite \u00e0 la mise en place de protocole d\u2019anesth\u00e9sie sans morphinique (OFA)","author":"Venier","key":"10.1016\/j.pharma.2021.08.003_bib0585"},{"key":"10.1016\/j.pharma.2021.08.003_bib0590","unstructured":"Institut canadien d\u2019information sur la sant\u00e9. Tendances pancanadiennes en mati\u00e8re de prescription d\u2019opio\u00efdes, de 2012 \u00e0 2016; 2017. [En ligne] Disponible : https:\/\/secure.cihi.ca\/free_products\/pan-canadian-trends-opioid-prescribing-2017-fr-web.pdf.[Consult\u00e9 le 15 novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0595","series-title":"Emergency department visits for drug misuse or abuse involving the pain medication tramadol","first-page":"8","author":"Bush","year":"2015"},{"year":"2018","series-title":"Les Qu\u00e9b\u00e9cois consomment plus d\u2019antid\u00e9presseurs que la moyenne canadienne [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0600"},{"key":"10.1016\/j.pharma.2021.08.003_bib0605","unstructured":"Statistique Canada. Consommation de m\u00e9dicaments sur ordonnance chez les Canadiens de 6 \u00e0 79 ans; 2015. [En ligne] Disponible : https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-003-x\/2014006\/article\/14032-fra.htm [Consult\u00e9 le 15 novembre 2020]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0610","unstructured":"OFMA. Progression du m\u00e9susage du fentanyl\u00a0: importance de l\u2019addictovigilance. [En ligne] Disponible\u00a0: http:\/\/www.ofma.fr\/fentanyl\/ [Consult\u00e9 le 18\u00a0mars 2021]."},{"key":"10.1016\/j.pharma.2021.08.003_bib0615","unstructured":"M\u00e9dicaments \u00e0 risque d\u2019usage d\u00e9tourn\u00e9 ou de d\u00e9pendance - ANSM\u00a0: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 [Internet]. [En ligne]. Disponible\u00a0: https:\/\/www.ansm.sante.fr\/Declarer-un-effet-indesirable\/Pharmacodependance-Addictovigilance\/Medicaments-a-risque-d-usage-detourne-ou-de-dependance\/(offset)\/4 [Consult\u00e9 le 15\u00a0novembre 2020]."},{"issue":"2","key":"10.1016\/j.pharma.2021.08.003_bib0620","article-title":"Perspective qu\u00e9b\u00e9coise et canadienne de la pratique pharmaceutique en \u00e9tablissement de sant\u00e9 pour 2016\u20132017","volume":"51","author":"Bussi\u00e8res","year":"2018","journal-title":"Pharmactuel"},{"year":"2019","series-title":"Sant\u00e9 Canada - Lignes directrices recommand\u00e9es dans les domaines de la s\u00e9curit\u00e9, du rapprochement des stocks et de la tenue de dossiers \u00e0 l\u2019intention des pharmaciens communautaires. [en ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0625"},{"year":"2017","series-title":"Le Canada envisage de classer le tramadol en opio\u00efde. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0630"},{"year":"2017","series-title":"Narcotic and Controlled Drug Regulations. [En ligne]","key":"10.1016\/j.pharma.2021.08.003_bib0635"},{"issue":"1","key":"10.1016\/j.pharma.2021.08.003_bib0640","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0018578718779005","article-title":"A Survey of Opioid Medication Stewardship Practices at Academic Medical Centers","volume":"54","author":"Phelps","year":"2019","journal-title":"Hosp Pharm"},{"issue":"4","key":"10.1016\/j.pharma.2021.08.003_bib0645","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0018578718809267","article-title":"Transformation of Hospital Pharmacist Opioid Stewardship","volume":"54","author":"Ghafoor","year":"2019","journal-title":"Hosp Pharm"},{"issue":"8","key":"10.1016\/j.pharma.2021.08.003_bib0325","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ajhp\/zxaa027","article-title":"Current state of opioid stewardship","volume":"77","author":"Ardeljan","year":"2020","journal-title":"Am J Health Syst Pharm"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450921001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450921001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:35:26Z","timestamp":1757720126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450921001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0003450921001206"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2021.08.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consommation des stup\u00e9fiants, substances assimil\u00e9es aux stup\u00e9fiants et psychotropes en \u00e9tablissement de sant\u00e9\u00a0: profil d\u2019un h\u00f4pital fran\u00e7ais et d\u2019un h\u00f4pital qu\u00e9b\u00e9cois","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}